TABLE 3.
Protein carrier/immunogenicity relationships of conjugates prepared with a 10-mer of γDPGA bound to BSA, rPA, rEPA, or TTa
| Conjugate | γDPGA (mol)/ protein (mol) | Anti-γDPGA (EU)
|
Anti-proteinc
|
||
|---|---|---|---|---|---|
| 2nd injection | 3rd injection | 2nd injection | 3rd injection | ||
| BSA/Br-Gly3-γDPGA10 | 18 | 1,900 | 1,800 | 5 | 19 |
| rEPA/Br-Gly3-γDPGA10 | 9 | 930 | 3,200 | 0.6 | 6 |
| rPA/Br-Gly3-γDPGA10 | 14 | 4,400 | 7,200 | 1 | 96 |
| rPA/Cys-Gly3-γDPGA10 | 21 | 5,500 | 7,500 | 0.1 | 2.2 |
| TT/Cys-Gly3-γDPGA10 | 11 | 420 | 7,800 | NTb | NT |
a
Five- to 6-week-old NIH general-purpose mice (n = 10) were injected subcutaneously with 2.5 μg of γDPGA as a conjugate 2 weeks apart and exsanguinated 7 days after the second or third injection. IgG anti-γDPGA and anti-rPA were measured by ELISA, and the results are expressed as the geometric means.
b
NT, not tested.
c
EU for anti-BSA and anti-rEPA and μg/ml for anti-rPA.